MILPITAS, Calif., June 24, 2025 (GLOBE NEWSWIRE) — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX
Isolated from a single, well-characterized induced pluripotent stem cell (iPSC) line, hiEX
“Exosomes offer exciting possibilities as cell-free tools in regenerative medicine,” said Dr. Ruby Tsai, CEO of Applied StemCell. “Our hiEX
By combining the scalability of iPSCs with rigorous quality control and the potential for fast gene knock-in into the parent line, hiEX
For more information, visit the product page: https://appliedstemcell.com/product/hiex-research-ipsc-exosomes/
About Applied StemCell
Applied StemCell is a biotechnology company dedicated to providing enabling tools and services for stem cell and genome editing research. With expertise in iPSC generation, differentiation, and custom genome engineering, Applied StemCell supports basic and discovery research through GMP and RUO platforms tailored to the needs of biotech, pharma, and academic researchers.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c077effa-97a8-4d71-a4ce-80c362bba629
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow